FGFR (Fibroblast growth factor receptors) are the receptors that bind to members of the fibroblast growth factor family of proteins.Pathological conditions involve some of these receptors. Achondroplasia can be brought on by a point mutation in FGFR3. Vertebrates have been found to contain five distinct membrane FGFRs, all of which are members of the tyrosine kinase superfamily (FGFR1, FGFR2, FGFR3, FGFR4, FGFR6). One of the most significant families of paracrine factors that function in the development process is the fibroblast growth factor family. They control which cells differentiate into mesoderm, the production of blood vessels, the growth of limbs, and the growth and differentiation of many different cell types.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V69461 | FGFR4-IN-8 | 2765240-52-4 | FGFR4-IN-8 (Compound 7v) is an ATP-competitive, selective covalent inhibitor of wild-type and mutant FGFR4. |
|
V0615 | FIIN-2 | 1633044-56-0 | FIIN-2 (FIIN 2; FIIN2) is a novel irreversible/covalent pan-FGFR inhibitor with potential anticancer activity. |
|
V77002 | Formononetin-d3-1 (formononetin-d3) | Formononetin-d3-1 is deuterated Formononetin. | |
|
V69449 | Gunagratinib (ICP-192) | 2211082-53-8 | Gunagratinib (ICP-192) is a low-toxic, orally bioactive pan-FGFR (fibroblast growth factor receptor) inhibitor that potently, selectively and irreversibly inhibits FGFR activity through covalent binding. |
|
V3131 | H3B-6527 | 1702259-66-2 | H3B-6527 is a potent, highly selective, orally bioavailable, covalent FGFR4 inhibitor with IC50 value of ~1.2 nM. |
|
V85864 | Infigratinib-Boc | 2504949-83-9 | Infigratinib-Boc is the BOC-protected Infigratinib |
|
V83667 | Infigratinib-d3 (BGJ-398-d3; NVP-BGJ398-d3) | ||
|
V97276 | IONIS-FGFR4Rx | 1416376-17-4 | IONIS-FGFR4Rx (ISIS 463588) is an antisense inhibitor of fibroblast growth factor receptor 4 (FGFR4) with potential for use in kidney disease research. |
|
|
V97337 | IONIS-FGFR4Rx sodium | IONIS-FGFR4Rx (ISIS 463588) sodium is an antisense inhibitor of fibroblast growth factor receptor 4 (FGFR4) with potential for use in kidney disease research. | |
|
V69450 | Irpagratinib (ABSK011) | 2230974-62-4 | Irpagratinib (ABSK011) is an orally bioactive fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor targeting FGFR4 (IC50<10 nM). |
|
V69474 | LC-MB12 | 2828438-38-4 | LC-MB12 is an orally bioactive PROTAC compound that targets FGFR2 degradation with DC50 of 11.8 nM. |
|
V76828 | Lenvatinib-d4 (E7080-d4) | 2264050-65-7 | Lenvatinib-d4 is the deuterated form of Lenvatinib. |
|
V80557 | Lenvatinib-d5 (E7080-d5) | Lenvatinib-d5 is the deuterated form of Lenvatinib. | |
|
V79962 | Multi-kinase-IN-5 | Multi-kinase-IN-5 (compound 15c) is a promising multi-kinase inhibitor. | |
|
V2671 | NSC-12 | 102586-30-1 | NSC-12 (also known as NSC12; NSC 172285) is an orally available pan-FGF trap able to inhibit FGF2/FGFR interaction and endowed with promising antitumor activity. |
|
V26847 | ODM-203 | 1430723-35-5 | ODM-203 is a potent and orally bioavailable inhibitor of FGFRandVEGFRfamilies inhibitor withIC50s of 11, 16, 6, 35 nM towards recombinant FGFR1, FGFR2, FGFR3 and FGFR4 as well as 26, 9, 5 nM towards VEGFR1, VEGFR2 and VEGFR3, respectively. |
|
V2723 | PD166866 | 192705-79-6 | PD166866, a member of a new structural class of tyrosine kinase inhibitors, the 6-aryl-pyrido[2,3-d]pyrimidines, is a a new nanomolar potent and selective small molecule inhibitor of FGFR (fibroblast growth factor-1 receptor) tyrosine kinase inhibitor with an IC50 of 52.4 nM. |
|
V2780 | PRN1371 | 1802929-43-6 | PRN1371 is a highly selective, potent, covalent, and irreversible FGFR1,2,3,4 inhibitor with IC50 values of 0.6, 1.3, 4.1 and 19.3 nM, respectively. |
|
V69482 | Recifercept (TA-46; sFGFR3) | 2226238-09-9 | Recifercept (TA-46) is a soluble recombinant fibroblast growth factor receptor 3 (FGFR3) molecule. |
|
V69463 | Resigratinib (KIN-3248) | 2750709-91-0 | Resigratinib (KIN-3248) is an FGFR tyrosine kinase inhibitor (TKI) (antagonist) with anti-tumor effects. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
